Abbott Laboratories Stays a Long-Term Buy at Reasonable Valuations After Q2 Beat and Exact Sciences Contribution

Quick Take

• Abbott Laboratories (ABT) remains a long-term buy recommendation despite post-Q2 share price appreciation, as analysts view the current valuation as reasonably priced rather than stretched after the earnings beat
• Q2 results beat consensus estimates and included positive contributions from Exact Sciences' growth in cancer diagnostics, validating Abbott's diversified medical devices and diagnostics strategy
• Abbott's diverse business mix — spanning medical devices, diagnostics, nutritionals, and established pharmaceuticals — provides defensive earnings characteristics and supports a premium-to-peers valuation multiple

Abbott Laboratories (NYSE: ABT) received a continued buy recommendation from analysts following its Q2 2026 earnings beat, with the assessment characterising current valuations as 'reasonably valued' rather than overextended — a nuanced framing that signals institutional conviction without urging aggressive accumulation at post-surge prices. The Q2 results were supported by Exact Sciences' ongoing growth in the cancer diagnostics segment, where Abbott's Cologuard colorectal cancer screening test continues to drive adherence-driven recurring revenue from the ageing US population. Medical devices — particularly Abbott's cardiac rhythm management and vascular intervention businesses — contributed to the beat.

Abbott's investment case rests on the convergence of multiple structural healthcare tailwinds: rising global chronic disease prevalence driving demand for monitoring devices (CGM for diabetes, cardiac diagnostics), an ageing population increasing diagnostics utilisation, and the post-COVID acceleration of point-of-care testing capabilities that Abbott expanded during the pandemic. The Exact Sciences contribution is particularly relevant: early cancer detection is one of the highest-growth segments in diagnostics, and Abbott's commercial infrastructure provides distribution reach that independent diagnostics companies cannot match.

Watch Abbott's Q3 FY26 revenue guidance — specifically the medical devices segment growth trajectory and whether Exact Sciences' cancer diagnostics volumes continue to accelerate. The FreeStyle Libre CGM (continuous glucose monitor) competitive positioning against Dexcom's G7 platform is the key device market share battle that determines Abbott's largest single product revenue stream. Any regulatory approvals for next-generation Abbott diagnostics platforms or Abbott's pipeline of minimally invasive cardiac devices would be the near-term re-rating catalysts.

Sources: seekingalpha.com

Market news synthesis. Not financial advice. Sources cited above.